Tags : NAV AAV9 vector


Pfizer Signs a License Agreement with Regenxbio for its NAV

Shots: Regenxbio to receive up front, development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio’s NAV AAV9 vector to develop & commercialize gene therapies for Friedreich’s ataxia The focus of the agreement is to strengthen Regenxbio’s intellectual property portfolio and the potential of NAV […]Read More